Standard

A patient with atrial fibrillation and diabetes : Selecting the optimal anticoagulant therapy regimen. / Obrezan, A. G.; Filippov, A. E.; Obrezan, A. A.

в: Russian Journal of Cardiology, Том 26, № 5, 4508, 11.06.2021.

Результаты исследований: Научные публикации в периодических изданиях › статья › Рецензирование

Harvard

Obrezan, AG, Filippov, AE & Obrezan, AA 2021, 'A patient with atrial fibrillation and diabetes: Selecting the optimal anticoagulant therapy regimen', Russian Journal of Cardiology, Том. 26, № 5, 4508. https://doi.org/10.15829/1560-4071-2021-4508

APA

Obrezan, A. G., Filippov, A. E., & Obrezan, A. A. (2021). A patient with atrial fibrillation and diabetes: Selecting the optimal anticoagulant therapy regimen. Russian Journal of Cardiology, 26(5), [4508]. https://doi.org/10.15829/1560-4071-2021-4508

Vancouver

Obrezan AG, Filippov AE, Obrezan AA. A patient with atrial fibrillation and diabetes: Selecting the optimal anticoagulant therapy regimen. Russian Journal of Cardiology. 2021 Июнь 11;26(5). 4508. https://doi.org/10.15829/1560-4071-2021-4508

Author

Obrezan, A. G. ; Filippov, A. E. ; Obrezan, A. A. / A patient with atrial fibrillation and diabetes : Selecting the optimal anticoagulant therapy regimen. в: Russian Journal of Cardiology. 2021 ; Том 26, № 5.

BibTeX

@article{8adaa6bf4d944ac893cb179174e29901,
title = "A patient with atrial fibrillation and diabetes: Selecting the optimal anticoagulant therapy regimen",
abstract = "Atrial fibrillation (AF) is a common arrhythmia in patients with type 2 diabetes (T2D). Patients with diabetes are at higher risk of AF than those without it. There is an increased risk of dysglycemia in AF. Patients with AF and concomitant diabetes are more likely to have coronary artery disease, hypertension, heart failure, while strokes in patients with AF and diabetes are more severe. Diabetes, in turn, causes the angiopathies and cardiopathy. There is a higher risk of both thrombotic and bleeding events in patients with AF and T2D. The article discusses the mutual burden of T2D and AF, as well as the risk scores for thrombotic, thromboembolic, and bleeding events. Anticoagulant therapy takes a special place in improving the prognosis in AF patients. Numerous studies and actual clinical practice have demonstrated the effectiveness of anticoagulants in the prevention of stroke and other comorbidities.",
keywords = "Anticoagulants, Atrial fibrillation, Comorbidity, Diabetes",
author = "Obrezan, {A. G.} and Filippov, {A. E.} and Obrezan, {A. A.}",
note = "Publisher Copyright: {\textcopyright} 2021, Silicea-Poligraf. All rights reserved.",
year = "2021",
month = jun,
day = "11",
doi = "10.15829/1560-4071-2021-4508",
language = "English",
volume = "26",
journal = " РОССИЙСКИЙ КАРДИОЛОГИЧЕСКИЙ ЖУРНАЛ",
issn = "1560-4071",
publisher = "Russian Society of Cardiology",
number = "5",

}

RIS

TY - JOUR

T1 - A patient with atrial fibrillation and diabetes

T2 - Selecting the optimal anticoagulant therapy regimen

AU - Obrezan, A. G.

AU - Filippov, A. E.

AU - Obrezan, A. A.

N1 - Publisher Copyright: © 2021, Silicea-Poligraf. All rights reserved.

PY - 2021/6/11

Y1 - 2021/6/11

N2 - Atrial fibrillation (AF) is a common arrhythmia in patients with type 2 diabetes (T2D). Patients with diabetes are at higher risk of AF than those without it. There is an increased risk of dysglycemia in AF. Patients with AF and concomitant diabetes are more likely to have coronary artery disease, hypertension, heart failure, while strokes in patients with AF and diabetes are more severe. Diabetes, in turn, causes the angiopathies and cardiopathy. There is a higher risk of both thrombotic and bleeding events in patients with AF and T2D. The article discusses the mutual burden of T2D and AF, as well as the risk scores for thrombotic, thromboembolic, and bleeding events. Anticoagulant therapy takes a special place in improving the prognosis in AF patients. Numerous studies and actual clinical practice have demonstrated the effectiveness of anticoagulants in the prevention of stroke and other comorbidities.

AB - Atrial fibrillation (AF) is a common arrhythmia in patients with type 2 diabetes (T2D). Patients with diabetes are at higher risk of AF than those without it. There is an increased risk of dysglycemia in AF. Patients with AF and concomitant diabetes are more likely to have coronary artery disease, hypertension, heart failure, while strokes in patients with AF and diabetes are more severe. Diabetes, in turn, causes the angiopathies and cardiopathy. There is a higher risk of both thrombotic and bleeding events in patients with AF and T2D. The article discusses the mutual burden of T2D and AF, as well as the risk scores for thrombotic, thromboembolic, and bleeding events. Anticoagulant therapy takes a special place in improving the prognosis in AF patients. Numerous studies and actual clinical practice have demonstrated the effectiveness of anticoagulants in the prevention of stroke and other comorbidities.

KW - Anticoagulants

KW - Atrial fibrillation

KW - Comorbidity

KW - Diabetes

UR - http://www.scopus.com/inward/record.url?scp=85117725634&partnerID=8YFLogxK

UR - https://www.mendeley.com/catalogue/06762925-80ab-3386-a7bc-e411f8092d8e/

U2 - 10.15829/1560-4071-2021-4508

DO - 10.15829/1560-4071-2021-4508

M3 - Article

AN - SCOPUS:85117725634

VL - 26

JO - РОССИЙСКИЙ КАРДИОЛОГИЧЕСКИЙ ЖУРНАЛ

JF - РОССИЙСКИЙ КАРДИОЛОГИЧЕСКИЙ ЖУРНАЛ

SN - 1560-4071

IS - 5

M1 - 4508

ER -

ID: 87872676